P
Philip J. Stephens
Researcher at Foundation Medicine
Publications - 237
Citations - 34693
Philip J. Stephens is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Cancer & Targeted therapy. The author has an hindex of 69, co-authored 236 publications receiving 29559 citations. Previous affiliations of Philip J. Stephens include Wellcome Trust Sanger Institute & Wellcome Trust.
Papers
More filters
Journal ArticleDOI
Mutations of the BRAF gene in human cancer
Helen Davies,Graham R. Bignell,Charles Cox,Philip J. Stephens,Sarah Edkins,S. M. Clegg,Jon W. Teague,Hayley Woffendin,Mathew J. Garnett,William Bottomley,Neil Davis,Ed Dicks,Rebecca Ewing,Yvonne Floyd,Kristian Gray,S. Hall,Rachel Hawes,Jaime Hughes,Vivian Kosmidou,Andrew Menzies,Catherine Mould,Adrian Parker,Claire Stevens,Stephen Watt,Steven Hooper,Rebecca Wilson,Hiran Jayatilake,Barry A. Gusterson,Colin Cooper,Janet Shipley,Darren Hargrave,Kathy Pritchard-Jones,Norman J. Maitland,Georgia Chenevix-Trench,Gregory J. Riggins,Darell D. Bigner,Giuseppe Palmieri,Antonio Cossu,Adrienne M. Flanagan,Andrew G. Nicholson,Judy W. C. Ho,Suet Yi Leung,Siu Tsan Yuen,Barbara L. Weber,Hilliard F. Seigler,Timothy L. Darrow,Hugh Paterson,Richard Marais,Christopher J. Marshall,Richard Wooster,Michael R. Stratton,P. Andrew Futreal +51 more
TL;DR: BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers, with a single substitution (V599E) accounting for 80%.
Journal ArticleDOI
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton,Alex Fichtenholtz,Geoff Otto,Kai Wang,Sean R. Downing,Jie He,Michael Schnall-Levin,Jared White,Eric M. Sanford,Peter An,James Sun,Frank Juhn,Kristina W. Brennan,Kiel Iwanik,Ashley Maillet,Jamie Buell,Emily White,Mandy Zhao,Sohail Balasubramanian,Selmira Terzic,Tina Richards,Vera Banning,Lazaro Garcia,Kristen Mahoney,Zac Zwirko,Amy Donahue,Himisha Beltran,Himisha Beltran,Juan Miguel Mosquera,Juan Miguel Mosquera,Mark A. Rubin,Mark A. Rubin,Snjezana Dogan,Cyrus V. Hedvat,Michael F. Berger,Lajos Pusztai,Matthias Lechner,Chris Boshoff,Mirna Jarosz,Christine Vietz,Alexander N. Parker,Vincent A. Miller,Jeffrey S. Ross,Jeffrey S. Ross,John Curran,Maureen T. Cronin,Philip J. Stephens,Doron Lipson,Roman Yelensky +48 more
TL;DR: A test based on massively parallel DNA sequencing to characterize base substitutions, short insertions and deletions (indels), copy number alterations and selected fusions across 287 cancer-related genes from routine formalin-fixed and paraffin-embedded (FFPE) clinical specimens is described.
Journal ArticleDOI
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens,Patrick S. Tarpey,Helen Davies,Peter Van Loo,Peter Van Loo,Christopher Greenman,Christopher Greenman,David C. Wedge,Serena Nik-Zainal,Sancha Martin,Ignacio Varela,Graham R. Bignell,Lucy R. Yates,Lucy R. Yates,Elli Papaemmanuil,David Beare,Adam Butler,Angela Cheverton,John Gamble,Jonathan Hinton,Mingming Jia,Alagu Jayakumar,David Jones,Calli Latimer,King Wai Lau,Stuart McLaren,David J. McBride,Andrew Menzies,L. Mudie,Keiran Raine,Roland Rad,Michael Spencer Chapman,Jon W. Teague,Douglas F. Easton,Anita Langerød,Ming Ta Michael Lee,Chen-Yang Shen,Benita Tan Kiat Tee,Bernice Wong Huimin,Annegien Broeks,Ana Cristina Vargas,Gulisa Turashvili,John W.M. Martens,Aquila Fatima,Penelope Miron,Suet-Feung Chin,Gilles Thomas,Sandrine Boyault,Odette Mariani,Sunil R. Lakhani,Sunil R. Lakhani,Marc J. van de Vijver,Laura van 't Veer,John A. Foekens,Christine Desmedt,Christos Sotiriou,Andrew Tutt,Carlos Caldas,Carlos Caldas,Jorge S. Reis-Filho,Samuel Aparicio,Anne Vincent Salomon,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Andrea L. Richardson,Peter J. Campbell,Peter J. Campbell,Peter J. Campbell,P. Andrew Futreal,Michael R. Stratton +69 more
TL;DR: Strong correlations between mutation number, age at which cancer was diagnosed and cancer histological grade are found, and multiple mutational signatures are observed, including one present in about ten per cent of tumours characterized by numerous mutations of cytosine at TpC dinucleotides.
Journal ArticleDOI
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M. Goodman,Shumei Kato,Lyudmila Bazhenova,Sandip Pravin Patel,Garrett M. Frampton,Vincent A. Miller,Philip J. Stephens,Gregory A. Daniels,Razelle Kurzrock +8 more
TL;DR: Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse cancers treated with various immunotherapies, and Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.
Journal ArticleDOI
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis,Michael E. Goldberg,Danielle Greenawalt,Matthew D. Hellmann,Mark M. Awad,Justin F. Gainor,Alexa B. Schrock,Ryan J. Hartmaier,Sally E. Trabucco,Siraj M. Ali,Julia A. Elvin,Gaurav Singal,Jeffrey S. Ross,David Fabrizio,Péter Szabó,Han Chang,Ariella Sasson,Sujaya Srinivasan,Stefan Kirov,Joseph D. Szustakowski,Patrik Vitazka,Robin Edwards,Jose A. Bufill,Neelesh Sharma,Sai-Hong Ignatius Ou,Nir Peled,Nir Peled,David R. Spigel,Hira Rizvi,Elizabeth Jimenez Aguilar,Brett W. Carter,Jeremy J. Erasmus,Darragh Halpenny,Andrew J. Plodkowski,Niamh Long,Mizuki Nishino,Warren Denning,Ana Galan-Cobo,Haifa Hamdi,Taghreed Hirz,Pan Tong,Jing Wang,Jaime Rodriguez-Canales,Pamela Villalobos,Edwin Roger Parra,Neda Kalhor,Lynette M. Sholl,Jennifer L. Sauter,Achim A. Jungbluth,Mari Mino-Kenudson,Roxana Azimi,Yasir Elamin,Jianjun Zhang,Giulia Costanza Leonardi,Fei Jiang,Fei Jiang,Kwok-Kin Wong,J. Jack Lee,Vassiliki A. Papadimitrakopoulou,Ignacio I. Wistuba,Vincent A. Miller,Garrett M. Frampton,Jedd D. Wolchok,Alice T. Shaw,Pasi A. Jänne,Philip J. Stephens,Charles M. Rudin,William J. Geese,Lee A. Albacker,John V. Heymach +69 more
TL;DR: Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.